The swift development, production, deployment and — most importantly — efficacy of the COVID-19 vaccines showcased the best in public-private collaboration. Recent headlines regarding the vaccines and their intellectual property (IP) and, in particular, patent rights, however, show how the two domains do not always agree.

Please click here to read the complete article by Meyer, Unkovic & Scott Intellectual Property Practice Group Chair David G. Oberdick, which originally appeared in Western Pennsylvania Healthcare News.